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THE NUCLEOSIDE ADENOSINE plays an important role in many physiological processes. Its actions are mediated by specific cell surface receptors coupled to G proteins (7, 13) . At least four adenosine receptors have been cloned and classified as A 1 , A 2A , A 2B , and A 3 subtypes (7, 13) . Adenosine is a potent dilator of cerebral vessels (9, 11) and has been implicated in the regulation of cerebral blood flow (16, 19) . We (11) previously investigated the receptors involved in adenosine-induced dilation in cerebral resistance arterioles. On the basis of agonist potency orders, we concluded that adenosine acts primarily via A 2 receptors to elicit cerebral vasodilation (11) . Since then, new and more specific pharmacological tools have been developed. The purpose of the present study was to use selective adenosine receptor agonists and antagonists to further identify the receptor subtypes involved in the cerebral vasodilator response to adenosine.
In the present study, we utilized a microvessel cannulation technique (3, 4) for the pressurization and study of parenchymal arterioles isolated from the rat brain. Our preparation has two important features. First, because of their unique origin, intracerebral arterioles are markedly sensitive to vasoactive substances released during functional and metabolic activity. Second, with our in vitro methodology, these vessels are capable of developing spontaneous myogenic tone without the aid of pharmacological constrictor agents, which may confound data interpretation.
METHODS
Vessel isolation and cannulation. The experimental protocols in the present study were approved by the Animal Care Committee of the University of Washington. Male SpragueDawley rats weighing 350-400 g were initially anesthetized with pentobarbital sodium (50 mg/kg ip). The technique for the isolation and cannulation of brain-penetrating arterioles has been described in detail in previous publications (3, 11, 12) . Briefly, a piece of cerebral cortex ϳ3 mm thick containing the first portion of the middle cerebral artery was dissected from the brain of Sprague-Dawley rats. The pia mater and its attached penetrating intracerebral arterioles were carefully separated from the parenchyma. A segment of intracerebral arteriole ϳ0.5-1.0 mm in length was excised and transferred to a temperature-controlled vessel chamber on the stage of an inverted microscope. The arteriole was cannulated at both ends with a system of concentric micropipettes consisting of a perfusion pipette within a holding pipette. After cannulation was completed, the vessel was pressurized to 60 mmHg and perfused intraluminally at a flow rate of 2 l/min with buffered saline (pH 7.4) containing 1% albumin. Vessel diameter was measured with a video micrometer.
Protocol. The vessel bath contained buffered saline (pH 7.3, no albumin) with fresh buffer circulating at a rate of 0.75 ml/min. After the bath temperature was raised to 37°C, viable vessels gradually developed spontaneous tone and contracted to a stable baseline diameter. Vessel reactivity was assessed by replacing the bath fluid with acidic (pH 6.8) and alkaline (pH 7.6) buffer. Vessels with a poor pH response (Ͻ15% dilation or constriction) were excluded from data collection.
In the first series of experiments, we compared the dilation responses of intracerebal arterioles to adenosine and to the A 2A receptor-specific agonist 2-p-(2-carboxyethyl)-phenethylamino-5Ј-N-ethylcarboxy-amidoadenosine (CGS-21680). Concentration-response curves were constructed by changing the bath solution in 10-fold concentration increments by means of a perfusion pump at 0.75 ml/min. Vessel diameter was monitored for 5 min between solution changes. After the response to the highest agonist concentration (0.1 mM for adenosine and 0.01 mM for CGS-21680, in alternate orders) had been determined, vessel diameter was restored to baseline (i.e., diameter before agonist application). The experiment was discontinued if vessel diameter did not recover to Ϯ10% of control within 20 min after washout. Hence, the higher (Ͼ0.1 mM) concentration of adenosine was not included in this study because arterioles remain maximally dilated for extended periods after treatment at this high concentration.
We conducted a series of experiments to determine whether repeated exposures to adenosine agonists might lead to degraded dilation responses. After one adenosine concentration-response curve was determined, vessel diameter was restored to baseline, and a second adenosine concentration-response curve was constructed using the same vessel. These experiments also served as time controls for the antagonist studies.
We next examined the ability of the A 2A receptor-specific
to attenuate dilation of intracerebral arterioles induced by adenosine and by CGS-21680. Concentration-response curves to each agonist (adenosine or CGS-21680) were constructed in the absence and presence of ZM-241385. Only one agonist was studied in each experiment. We also compared the antagonist action of ZM-241385 with the nonselective adenosine antagonist 5-amino-9-chloro-2-(2-furyl)1,2,4-triazolo[1,5-c]quinazoline (CGS-15943). In addition, we obtained concentrationresponse curves to adenosine in the presence of both CGS-15943 and ZM-241385.
To further confirm that adenosine-induced dilation in cerebral arterioles is predominantly mediated by A2 receptors, we also evaluated the concentration responses of intracerebral arterioles to adenosine in the absence and presence of 0.1 M 8-cyclopentyl-1,3-dipropylxanthine (CPX, an A1 receptor-selective antagonist) and 0.1 M 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(Ϯ)-dihydropyridine-3,5-dicarboxylate (MRS-1191, an A3 receptor-selective antagonist). To assess the specificity of action of ZM-241385, we determined the effect of this antagonist (0.1 M) on dilation of intracerebral arterioles elicited by 10 M adenosine, 10 M ATP, and pH 6.8 buffer. ATP was applied via intraluminal perfusion (11), whereas both adenosine and pH 6.8 buffer were applied adventitially by exchanging fluid in the tissue bath, and reapplied in the presence of 0.1 M ZM-241385.
Drugs and solutions. The composition of the buffered saline solution was as follows (in mM): 144.0 NaCl, 3.0 KCl, 2.5 CaCl2, 1.5 MgSO4, 5.0 glucose, 2.0 pyruvate, 0.02 EDTA, 2.0 MOPS, and 1.2 NaH2PO4. Adenosine, CGS-21680, CGS-15943, CPX, MRS-1191, and ATP were obtained from Sigma (St. Louis, MO). ZM-241385 was purchased from Tocris Cookson (Ballwin, MO). SCH-58261 was a generous gift from Schering-Plough Research Institute (Milan, Italy). Adenosine, ATP, and CGS-21680 (hydrochloride) were dissolved directly into the MOPS-buffered saline solution. CPX, CGS-15943, MRS-1191, and ZM-241385 were dissolved in DMSO to yield stock solutions of 1-10 mM. Subsequent dilutions were made with buffered saline, and pH was adjusted to 7.3.
Data analysis. All data are expressed as means Ϯ SE. Only one vessel was studied from each animal. For comparison of responses to vasoactive agents, internal vessel diameters were normalized as a percentage of control diameters (diameters measured after the development of steady tone at 60 mmHg of intraluminal pressure and 37°C). Data and statistical analyses were performed with GraphPad Prism 3.0 software (San Diego, CA). The agonist concentrations required to cause 25 and 50% of maximum dilation observed (EC 25 and EC50 values, respectively) were obtained by averaging data from individual concentration-response curves. Comparisons between concentration-response curves were made using two-way analysis of variance (ANOVA), followed by the Bonferroni method for multiple group comparisons. A value of P Ͻ 0.05 was considered significant.
RESULTS
Intracerebral arterioles in this study (n ϭ 94) spontaneously constricted to 63 Ϯ 1% of their maximally dilated (passive) diameter as the bathing medium was warmed to 37°C. Average vessel diameter after spontaneous tone development was 47 Ϯ 1 m (range: 29-72 m). As is characteristic of cerebral arterioles, these vessels are markedly sensitive to pH changes. A bath pH of 7.6 led to a constriction of 24 Ϯ 1% from baseline diameter (pH 7.3), whereas decreasing pH to 6.8 dilated the vessels by 27 Ϯ 1%. We compared the concentration-dependent dilations of intracerebral arterioles to adenosine and CGS-21680 (Fig. 1 ). The concentration-response curves showed significant (P Ͻ 0.05) differences, with ϪlogEC 50 values of 6.5 Ϯ 0.2 for adenosine and 8.6 Ϯ 0.3 for CGS-21680. Although CGS-21680 has a lower dilator threshold (0.1 nM) than adenosine (1 nM), its dilator effect flattened out at 1 M and was surpassed by adenosine at a concentration of 10 M. Adenosine concentration-response curves are reproducible when repeated in the same vessel (Fig.  1B) and do not degrade with time. Figure 2 and Table 1 compare the effects of 0.1 M ZM-241385 on CGS-21680 and adenosine dose-response curves. ZM-241385 almost completely inhibited CGS-21680-induced dilation, leading to an 156-fold increase of EC 25 values (Table 1) . On the other hand, it only partially attenuated dilation induced by adenosine, increasing EC 25 values by only 16-fold. The almost complete inhibition of CGS-21680 suggests that ZM-241385 is an effective antagonist of the A 2A receptor. On the other hand, neither the A 1 receptor-selective antagonist CPX (0.1 M) nor the A 3 receptorselective antagonist MRS-1191 (0.1 M) affected the dilator responses of intracerebral arterioles to adenosine (Fig. 3) .
We also evaluated the effect of the nonselective adenosine antagonist CGS-15943 on the dilator responses of intracerebral arterioles to adenosine. CGS-15943 attenuated adenosine-induced dilation in a concentration-dependent manner (Fig. 4) To assess the specificity of the inhibitory action of ZM-241385, we determined its effects on dilation induced by ATP (intraluminal application) and acidic (pH 6.8) buffer. As shown in Fig. 5 , 0.1 M ZM-241385 significantly attenuated adenosine-induced dilation of intracerebral arterioles but did not affect the dilator responses to ATP and acidic buffer. Because DMSO was used as a solvent in some of the above experiments, we evaluated the effect of various concentra- tions of DMSO on intracerebral arterioles. As depicted in Fig. 6 , buffer containing as little as 0.5% DMSO caused pronounced dilation of intracerebral arterioles. In the present study, the DMSO concentration in all test solutions did not exceed 0.1%.
DISCUSSION
We (11) have previously shown that adenosine-induced dilation of brain parenchymal arterioles occurred mainly by activation of A 2 adenosine receptors. The present study extends these earlier findings by providing the first evidence that both A 2A and A 2B receptor subtypes mediate adenosine-induced dilation in cerebral arterioles in vitro.
Two findings in the present study strongly suggest that A 2A receptors are involved in adenosine-induced dilation of rat intracerebral arterioles. First, the selective A 2A receptor agonist CGS-21680 induced marked concentration-dependent dilation in these arterioles. Second, the relatively selective A 2A receptor antagonist ZM-241385 inhibited the dilation responses to both Values are means Ϯ SE; n, number of vessels. Control diameter, vessel diameter after tone development at 37°C and 60 mmHg of intraluminal pressure. 1 M) significantly attenuated the dilation response of intracerebral arterioles to 10 M adenosine (n ϭ 9 vessels) but had no effect on dilator responses to 10 M ATP (n ϭ 6 vessels) and acidic (pH 6.8) buffer (n ϭ 11 vessels). ATP was applied by intraluminal perfusion, whereas both adenosine and acidic buffer were applied adventitially (into the vessel chamber). Values are means Ϯ SE. *P Ͻ 0.001 vs. adenosine.
CGS-21680 and adenosine. CGS-21680 is a highly selective agonist that is virtually ineffective in A 2B receptors as well as other adenosine receptor subtypes (6, 7). On the other hand, ZM-241385 is only modestly selective for A 2A over A 2B receptors, with a reported A 2A versus A 2B receptor selectivity of 30-to 80-fold in guinea pig functional preparations (17) and a ϳ60-fold selectivity in human receptor functional assays (15) . In the present study, however, ZM-241385 almost completely abolished the vasodilation induced by CGS-21680 without affecting the vasodilation induced by intraluminal ATP and pH changes in the extraluminal bath, suggesting that it is both an effective and specific antagonist for the A 2A receptor in rat intracerebral arterioles. A robust response to CGS-21680, together with inhibition of vasodilation by ZM-241385, suggests that A 2A receptors at least partially mediate the dilator response to adenosine.
Although no selective receptor antagonists are currently available to unequivocally assess the role of A 2B receptors in adenosine-induced dilation, our results nevertheless suggest that such receptors may play a role in the dilation response to adenosine, at least at concentrations Ͼ 1 M. Two lines of evidence support the notion that both A 2A and A 2B receptor subtypes are coupled to adenosine-induced dilation in cerebral arterioles in the rat. First, adenosine, which is capable of activating both receptor subtypes, caused a greater maximal dilation than the specific agonist CGS-21680. Second, ZM-241385, the relatively selective A 2A receptor antagonist, only partially inhibited dilation induced by adenosine but almost completely blocked CGS-21680-induced dilation. The significantly greater dilation by adenosine compared with that caused by CGS-21680 occurred at concentrations Ͼ 1 M. We therefore speculate that at lower concentrations, both adenosine and CGS-21680 primarily activate the A 2A receptor, whereas at higher concentrations (Ͼ1 M), adenosine but not CGS-21680 also activates the A 2B receptor to cause greater maximal dilator effects. Such reasoning is consistent with the concept of high (A 2A ) and low (A 2B ) affinity adenosine A 2 receptors (1, 5) .
To further assess the role of A 2B receptors, we determined the effect of the adenosine antagonist CGS-15943 on adenosine-induced dilation in intracerebral arterioles. CGS-15943 has recently been reported to be a potent and relatively selective inhibitor of A 2B receptor-induced dilation in piglet coronary arterioles (8) . In that study, 0.1 M CGS-15943 attenuated adenosineand 5Ј-N-ethylcarboxamideadenosine (NECA)-induced vasodilation only at high agonist concentrations (Ն1 M) but not at low concentrations, suggesting that CGS-15943 preferentially inhibited the low-affinity (A 2B ) receptors. In contrast, the inhibitory effect of CGS-15943 in this study did not appear to be restricted to high adenosine concentrations but was apparent throughout the entire concentration range of adenosine studied. CGS-15943 (1 M) abolished the adenosine-induced dilation up to an adenosine concentration of 1 M and potently attenuated dilation responses to higher concentrations of adenosine. Such an observation is consistent with the nonselectivity of CGS-15943 for the A 2A and A 2B receptor subtypes in most tissues (6, 7) . Parenthetically, at human receptors expressed in cell lines, CGS-15943 has been reported to have a higher A 2A versus A 2B receptor selectivity than ZM-241385. We concluded that CGS-15943 did not selectively attenuate the A 2B receptor-mediated dilation in this study and thus is not useful for identifying A 2 receptor subtypes in cerebral arterioles.
In the study by Hein et al. (Fig. 2) . Moreover, addition of 0.1 M ZM-241385 to CGS-15943 in this study did not lead to further inhibition of the dilation responses that remained after blockade by CGS-15943. Such data is consistent with the notion that 0.1 M ZM-241385 is relatively A 2A receptor selective and has minimal effects on A 2B receptors in cerebral arterioles.
It is now well accepted that A 2 receptors mediate vasodilation to adenosine in the cerebral vasculature (16) as well as in a variety of other vascular beds (14) . The present study, in addition, provides evidence against the involvement of both A 1 and A 3 receptors by showing that the adenosine-induced dilation of cerebral arterioles was neither affected by the A 1 receptorselective antagonist CPX nor by the A 3 receptor-selec- (2) reported that topical application of CGS-21680 increased cortical blood flow in rats and that ZM-241385 attenuated the cortical response to topically applied adenosine. However, at the very high concentration used (150 M), ZM-241385 lacks selectivity. Moreover, no concentration-response curves were obtained. Thus the results of the study by Coney and Marshall (2) cannot discriminate between A 2A and A 2B receptors. In another in vivo study in rats (18) , dilations of pial arterioles (closed cranial window preparation) to adenosine and NECA were attenuated by topical ZM-241385 (1 M). Because alloxazine (1 M) caused a greater suppression of adenosine and NECA dose responses than ZM-241385, the authors concluded that the A 2B subtype mediates adenosine-induced dilation in cerebral vessels. Such an interpretation is questionable because of the lack of selectivity of alloxazine, which is only about nine times more potent at A 2B receptors than at A 2A receptors (6) .
We (11, 12) as well as other investigators (8) have discussed in detail the inherent advantages of the isolated vessel preparation over in vivo methods. Those include the precise control of physical and chemical factors and relative immunity to confounding problems such as tissue uptake and hormonal changes. With the pressure myograph approach used in the present study, vessels developed spontaneous tone without the need for pharmacological vasoconstrictors. As in previous studies (11, 12) , we were careful to preserve the viability and responsiveness of isolated cerebral arterioles with the use of criteria such as myogenic tone development at 37°C, rhythmic vasomotion, and reactivity to agents such as pH changes. In the present study, intraluminal application of 10 M ATP, an endothelium-dependent vasodilator (20) , caused a 35% dilation of intracerebral arterioles, confirming the functional integrity of the endothelium in these cannulated vessels.
However, the cannulated and perfused cerebral arterioles in this preparation tended to lose basal tone and/or pH reactivity after repeated dose-response determinations or after prolonged exposure to high agonist concentrations. A similar fragility has also been described for coronary arterioles (8) . As stated in METH-ODS, we took precautions to assure the reliability of data collection. For example, experiments were stopped if vessel diameter did not recover to Ϯ10% of control values after washout. In addition, vessels that lost pH reactivity (Ͻ15%) at the end of an experiment were also excluded from data analysis. In our hands, multiple exposures to adenosine did not degrade vascular responses, as evidenced by our time control experiments (Fig. 1B) , which revealed that agonist concentration-response relationships were reproducible when repeated in the same experiment. Nevertheless, because of the inability of these vessels to regain tone after exposure to very high agonist concentrations (Ͼ0.1 mM), we did not perform classical pharmacological analyses such as Schild regressions (10) . In addition, the vessels in this study were highly sensitive to organic solvents such as DMSO. As shown in Fig. 5 , even a 0.5% concentration of DMSO led to a marked dilation of ϳ26%. This sensitivity to solvent concentration thus precluded us from studying drugs with low organic solvent solubility. For example, the A 2A receptor-selective antagonist SCH-58261 has a maximal solubility of 0.5 M in 10% DMSO solution (solubility data supplied by Schering-Plough Research Institute, Milan, Italy). Thus the maximum concentration of SCH-58261 that can be used in the present study without significant effect on basal diameter is 5 nM. Because this concentration of SCH-58261 only had a weak inhibitory effect on CGS-21680 dose responses (data not shown), we were unable to compare its effect in a meaningful manner with ZM-241385.
In summary, the results of this study provide functional evidence that A 2A receptors mediate dilation of cerebral arterioles to adenosine. Despite the current lack of highly selective A 2B receptor antagonists, our results also suggest that A 2B receptors are probably involved in adenosine-induced dilation. At lower concentrations of adenosine, the response is likely to be mediated primarily by the A 2A receptor, whereas at higher concentrations (Ͼ1 M), A 2B receptors may also be activated to contribute to the dilation response.
